A new saliva test can measure the amount of potential carcinogens stuck to a person's DNA, interfering with the action of genes involved in health and disease, and could lead to a commercial test to help determine risks for cancer and other diseases.
MorphoSys AG announced that the first patient in a Phase 1/2a clinical trial of its cancer antibody MOR202 has been dosed. MOR202 is directed against a therapeutic target which is highly expressed in blood cancers.
ReNeuron Group reports that the Data Safety Monitoring Board for the Phase 1 clinical trial of its ReN001 stem cell therapy for stroke patients has recommended that the trial advances to the evaluation of a higher dose of ReN001.
Researchers have reported results from a trial that showed that an intravenously-delivered viral therapy can consistently infect and spread within tumors without harming normal tissues in humans.
Scientists have shown that a particular white blood cell plays a direct role in the development and spread of cancerous tumors. This work points toward novel strategies for treating early-stage cancers.
Drugmaker Pfizer Inc. is extending by a day its tender offer for pain drug developer Icagen, after the number of shares tendered by its previous deadline fell just short of what Pfizer needed.
Pharming Group and Swedish Orphan Biovirum announce that Ruconest (INN conestat alfa), a recombinant version of the human protein C1 inhibitor (C1INH), will launch in The Netherlands after the Dutch regulatory authority gave final approval.
Gene therapy plus an injection of copper dramatically improved survival in mice with a condition that mimics the often fatal childhood disorder Menkes disease, according to a study by researchers at the National Institutes of Health.
Researchers funded by the National Institutes of Health have converted stem cells from the human endometrium into insulin-producing cells and transplanted them into mice to control the animals’ diabetes.
Horizon Pharma Inc. recorded an $11.6 million loss in the second quarter, its last quarter before the completion of an initial public offering of stock last month.
Dr. Reddy's Laboratories Ltd. said on Aug. 31 that it settled a lawsuit brought by Pfizer Inc. over a generic version of Pfizer's cholesterol drug Lipitor.
Keryx Biopharmaceuticals Inc. said on Aug. 31 that an independent monitoring board recommended that its late-stage study of a potential colorectal cancer treatment can continue as planned until it is completed.
University of California, Davis researchers developed a computer model to test the effects of medications for arrhythmia, or abnormal heart rhythm, before they are used in patients.
Life Technologies is now offering Protein Thermal Shift complete solution, an application for Applied Biosystems real-time PCR systems that enables analysis of protein thermal stability.
Special Optics offers objective lens solutions optimized for use in two-photon microscopy systems. These apochromatic objectives are customized with high numerical apertures and long working distances for use with various sample sizes and applications.